TotalMarketCap

AgomAb Therapeutics

AGMBNasdaq BelgiumHealth CareBiotechnology: Biological Products (No Diagnostic Substances)

Market cap

$332.424 M

$6.75 -1.46%

Close of 6 Nov 2026

As of 6 Nov 2026, AgomAb Therapeutics (AGMB) has a market capitalization of $332.4M. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

—

Not reported

Earnings

—

Not reported

Shares outstanding

34,167,168

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 163 →
  1. #75IRulya TherapeuticsIRLA$335.1M
  2. #76Autolus TherapeuticsAUTL$332.7M
  3. #77AgomAb TherapeuticsAGMB$332.4M
  4. #78Fennec PharmaceuticalsFENC$327.6M
  5. #79ProkidneyPROK$322.0M

What if AgomAb Therapeutics were worth as much as…

Open the what-if tool →

Gold $28.2T

$573,361.11

Per share 84,942× higher

Bitcoin $1.53T

$31,023.57

Per share 4,596× higher

Apple $5.02T

$101,847.49

Per share 15,089× higher

Or at a round number

$500.0M$1.00B$2.00B$5.00B

Where these numbers come from

Share counts and financials for AgomAb Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.